Assays for the identification and quantification of sialic acids: Challenges, opportunities and future perspectives

Cheeseman, Jack; Kuhnle, Gunter Georg; Spencer, Daniel I. R.; Osborn, Helen M. I.

doi:10.1016/j.bmc.2020.115882

Cited by 26 publications

(19 citation statements)

References 92 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This perhaps highlights the need for easier and more accurate assays for sialic acid analysis. [10] The study did however offer some interesting insights that sialic acid may be useful for tracking tumour staging and grading, with statistically significant (p < 0.05) elevations in serum LSA levels found between healthy controls and patients with tumours stage I-IV. These findings were built upon by a more recent study, that included a larger sample size.…”

Section: Bladder Cancermentioning

confidence: 89%

“…Colorimetric methods are relatively inaccurate for sialic acid quantitation [10], where the authors make the correct assertion that their enzymatic method is most likely more accurate.…”

Section: Atherosclerosismentioning

confidence: 99%

“…This can be performed using a variety of assays, falling into four main categories: colorimetric, fluorometric, enzymatic and chromatographic. [10] Some of the most common assays are: thiobarbituric acid assay [11], orcinol/resorcinol assays [12,13] (colorimetric), 3,5-diaminobenzoic acid [14] (fluorometric), pyruvate release via sialic acid aldolase [15] (enzymatic) and labelling of sialic acid with 1,2-Diamino-4,5methyleneoxybenzene [16] (DMB) followed by HPLC/UPLC analysis (chromatographic).…”

Section: Quantification Of Sialic Acidmentioning

confidence: 99%

See 2 more Smart Citations

Sialic Acid As A Potential Biomarker for Cardiovascular Disease, Diabetes and Cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease (CVD), diabetes and cancer pose increasing global healthcare burdens. New biomarkers could enable earlier diagnosis of these diseases, leading to more effective treatment and lower associated healthcare burden. Elevated sialic acid concentration in plasma and serum has been positively correlated with the presence of CVDs, diabetes and the development of malignant tumors. This article reviews the use of total sialic acid (TSA), bound sialic acid (BSA) and free sialic acid (FSA) as potential biomarkers for these diseases and makes a comparison with existing markers. Elevated sialic acid has been shown to be indicative of the pathogenesis of CVD, diabetes and malignant tumors. While not a specific marker for one disease there is promise in utilizing sialic acid as a marker for monitoring disease progression and effectiveness of treatment programs.

show abstract

Section: Bladder Cancermentioning

confidence: 89%

“…Colorimetric methods are relatively inaccurate for sialic acid quantitation [10], where the authors make the correct assertion that their enzymatic method is most likely more accurate.…”

Section: Atherosclerosismentioning

confidence: 99%

Section: Quantification Of Sialic Acidmentioning

confidence: 99%

See 1 more Smart Citation

Sialic Acid As A Potential Biomarker for Cardiovascular Disease, Diabetes and Cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…UHPLC also does not suffer from many of the issues that hinder other assays for the quantitative analysis of sialic acids, for example that other compounds present in complex biological samples can affect the quantitation procedure by reacting with the reagents used. [30] Once the standards were qualitatively assessed, the next stage was to utilise the standards for the quantitation of sialic acids in biological samples. Samples that contained acetylated sialic acid derivatives were chosen to validate Neu5,9Ac 2 and Neu4,5Ac 2 as quantitative standards.…”

Section: Utilisation Of Standards For Quantitationmentioning

confidence: 99%

Quantitative Standards of 4‐O‐Acetyl‐ and 9‐O‐Acetyl‐N‐Acetylneuraminic Acid for the Analysis of Plasma and Serum

et al. 2022

Self Cite

View full text Add to dashboard Cite

N‐Acetylneuraminic acid (sialic acid, Neu5Ac) is one of a large, diverse family of nine‐carbon monosaccharides that play roles in many biological functions such as immune response. Neu5Ac has previously been identified as a potential biomarker for the presence and pathogenesis of cardiovascular disease (CVD), diabetes and cancer. More recent research has highlighted acetylated sialic acid derivatives, specifically Neu5,9Ac2, as biomarkers for oral and breast cancers, but advances in analysis have been hampered due to a lack of commercially available quantitative standards. We report here the synthesis of 9‐O‐ and 4‐O‐acetylated sialic acids (Neu5,9Ac2 and Neu4,5Ac2) with optimisation of previously reported synthetic routes. Neu5,9Ac2 was synthesised in 1 step in 68 % yield. Neu4,5Ac2 was synthesised in 4 steps in 39 % overall yield. Synthesis was followed by analysis of these standards via quantitative NMR (qNMR) spectroscopy. Their utilisation for the identification and quantification of specific acetylated sialic acid derivatives in biological samples is also demonstrated.

show abstract

Bacterial Enzyme Assay for Mucin Glycan Degradation

Katoh,

Ashida

2024

Methods in Molecular Biology

View full text Add to dashboard Cite

Assays for the identification and quantification of sialic acids: Challenges, opportunities and future perspectives

Cited by 26 publications

References 92 publications

Sialic Acid As A Potential Biomarker for Cardiovascular Disease, Diabetes and Cancer

Sialic Acid As A Potential Biomarker for Cardiovascular Disease, Diabetes and Cancer

Quantitative Standards of 4‐O‐Acetyl‐ and 9‐O‐Acetyl‐N‐Acetylneuraminic Acid for the Analysis of Plasma and Serum

Bacterial Enzyme Assay for Mucin Glycan Degradation

Contact Info

Product

Resources

About